Corcept Therapeutics Inc CORT
We take great care to ensure that the data presented and summarized in this overview for CORCEPT THERAPEUTICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CORT
View all-
Black Rock Inc. New York, NY16.5MShares$928 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$561 Million0.01% of portfolio
-
Ingalls & Snyder LLC New York, NY8.27MShares$464 Million14.93% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny6.51MShares$365 Million0.48% of portfolio
-
Parallel Advisors, LLC3.81MShares$214 Million4.22% of portfolio
-
State Street Corp Boston, MA3.52MShares$197 Million0.01% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.53MShares$142 Million0.03% of portfolio
-
Novo Holdings Hellerup, G72.41MShares$135 Million7.8% of portfolio
-
Geode Capital Management, LLC Boston, MA2.38MShares$133 Million0.01% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA1.58MShares$88.7 Million0.06% of portfolio
Latest Institutional Activity in CORT
Top Purchases
Top Sells
About CORT
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
Insider Transactions at CORT
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 11
2024
|
Daniel N Swisher Jr |
SELL
Open market or private sale
|
Direct |
2,200
-100.0%
|
$129,800
$59.88 P/Share
|
|
Nov 11
2024
|
Daniel N Swisher Jr |
BUY
Exercise of conversion of derivative security
|
Direct |
2,200
+50.0%
|
$26,400
$12.13 P/Share
|
|
Nov 04
2024
|
William Guyer Chief Development Officer |
SELL
Open market or private sale
|
Direct |
3,394
-36.93%
|
$162,912
$48.97 P/Share
|
|
Nov 04
2024
|
William Guyer Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,394
+26.97%
|
$71,274
$21.65 P/Share
|
|
Nov 01
2024
|
William Guyer Chief Development Officer |
SELL
Open market or private sale
|
Direct |
6,606
-53.27%
|
$317,088
$48.97 P/Share
|
|
Nov 01
2024
|
William Guyer Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,606
+34.75%
|
$138,726
$21.65 P/Share
|
|
Oct 01
2024
|
William Guyer Chief Development Officer |
SELL
Open market or private sale
|
Direct |
10,000
-63.31%
|
$460,000
$46.28 P/Share
|
|
Oct 01
2024
|
William Guyer Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+38.77%
|
$210,000
$21.65 P/Share
|
|
Oct 01
2024
|
Gary Charles Robb Chief Business Officer |
SELL
Open market or private sale
|
Direct |
11,000
-32.57%
|
$506,000
$46.28 P/Share
|
|
Oct 01
2024
|
Gary Charles Robb Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
11,000
+24.57%
|
$33,000
$3.29 P/Share
|
|
Sep 27
2024
|
Gary Charles Robb Chief Business Officer |
BUY
Bona fide gift
|
Indirect |
830
+4.12%
|
-
|
|
Sep 18
2024
|
Gary Charles Robb Chief Business Officer |
SELL
Other acquisition or disposition
|
Indirect |
7,250
-100.0%
|
-
|
|
Sep 18
2024
|
Gary Charles Robb Chief Business Officer |
SELL
Bona fide gift
|
Direct |
870
-3.68%
|
-
|
|
Sep 17
2024
|
Gary Charles Robb Chief Business Officer |
SELL
Bona fide gift
|
Direct |
300
-1.25%
|
-
|
|
Sep 03
2024
|
Joseph Douglas Lyon |
BUY
Grant, award, or other acquisition
|
Direct |
744
+3.69%
|
$12,648
$17.13 P/Share
|
|
Sep 03
2024
|
Joseph Douglas Lyon |
SELL
Payment of exercise price or tax liability
|
Direct |
129
-1.39%
|
$4,515
$35.3 P/Share
|
|
Sep 03
2024
|
Atabak Mokari Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
800
+3.15%
|
$13,600
$17.13 P/Share
|
|
Sep 03
2024
|
Atabak Mokari Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
143
-1.21%
|
$5,005
$35.3 P/Share
|
|
Sep 03
2024
|
Sean Maduck |
BUY
Grant, award, or other acquisition
|
Direct |
916
+0.54%
|
$15,572
$17.13 P/Share
|
|
Sep 03
2024
|
Sean Maduck |
SELL
Payment of exercise price or tax liability
|
Direct |
232
-0.27%
|
$8,120
$35.3 P/Share
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 972K shares |
|---|---|
| Grant, award, or other acquisition | 22.8K shares |
| Bona fide gift | 4.4K shares |
| Other acquisition or disposition | 27.8K shares |
| Payment of exercise price or tax liability | 350K shares |
|---|---|
| Bona fide gift | 6.57K shares |
| Other acquisition or disposition | 37.1K shares |
| Open market or private sale | 354K shares |